New Data Boosts Nanobiotix's Radiotherapy-Transformation Strategy
Executive Summary
Nanobiotix gains more clinical evidence to support its nanoparticle technology in combination with radiotherapy to enhance treatment outcomes in cancer patients.
You may also be interested in...
Nanobiotix Expands US Leadership Team
Nanobiotix has made two new appointments – one related to clinical development and the other to investor relations – to its US team.
Small-Cap Recap: Fiscal 2016 Spells Sea Change For Angle; Cellnovo; Novacyt; Nanobiotix
A status update on four startups working in the molecular diagnostics and radiotherapy sectors.
INTERVIEW: Nanobiotix’s nanoparticles bring big benefits to radiotherapy
Bells and whistles may sound nice but simplicity always wins hands down. Indeed, keeping it simple was how cancer nanotech firm Nanobiotix captured public investors’ interest to successfully raise €14.2 million ($18.5 million) when it floated on the EuroNext stock exchange last year. Not a bad outcome for an early clinical stage company amidst a sluggish medtech IPO market.